Events Partner Content 3rd Microbiome Movement – Maternal & Infant Health Summit Treatment creation for maternal and infant microbiome
News FDA clears Ionis drug as first therapy for rare disease FCS Ionis Pharma's Tryngolza (olezarsen) has become the first FDA-approved drug therapy for adults with rare disease familial chylomicronaemia syndrome.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
